MedTrace Logo

Ticagrelor and Endothelial Function

NCT02261922 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-10-10

No results posted yet for this study

Summary

To evaluate the effect of ticagrelor on endothelial function as measured by flow mediated dilation of the brachial artery. This will be compared to prasugrel.

Conditions

  • Antiplatelet Agents; Endothelial Function; Pleotropic Effects

Interventions

DRUG

ticagrelor

DRUG

prasugrel

Sponsors & Collaborators

  • Hotel Dieu de France Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-10-31
Completion
2015-11-30

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02261922 on ClinicalTrials.gov